ONCIMMUNE: Protagen – a cracking good acquisition | Corporate | 143p vs 140p
ONCIMMUNE - Corporate | 143p vs 140p (+57%)Protagen – a cracking good acquisition
Oncimmune acquires Protagen Diagnostics AG
Transaction terms
A high-quality operation and business anchor in Europe
Delivering on 3-year forward strategy
Oncimmune acquires Protagen Diagnostics AG
Oncimmune Holdings and its subsidiaries are engaged in cancer diagnosis.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.